Toll Free: 1-888-928-9744
Published: Dec, 2014 | Pages:
57 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Review, H2 2014', provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Overview 6 Therapeutics Development 7 Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Overview 7 Pipeline Products for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis 8 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics under Development by Companies 9 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline Products Glance 10 Clinical Stage Products 10 Early Stage Products 11 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Products under Development by Companies 12 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Companies Involved in Therapeutics Development 13 Altor BioScience Corporation 13 AstraZeneca PLC 14 Boston Biomedical, Inc. 15 Daiichi Sankyo Company, Limited 16 Dendreon Corporation 17 Mirati Therapeutics Inc. 18 Novartis AG 19 Sanofi 20 Teva Pharmaceutical Industries Limited 21 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Therapeutics Assessment 22 Assessment by Monotherapy Products 22 Assessment by Target 23 Assessment by Mechanism of Action 25 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 ALT-801 - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 AZD-4547 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 BBI-503 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 cabazitaxel - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 CEP-11981 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 dovitinib lactate - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 lapuleucel-t - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 mocetinostat - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 tigatuzumab - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Recent Pipeline Updates 49 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects 54 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products 55 Appendix 56 Methodology 56 Coverage 56 Secondary Research 56 Primary Research 56 Expert Panel Validation 56 Contact Us 57 Disclaimer 57
List of Tables Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), H2 2014 7 Number of Products under Development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Comparative Analysis, H2 2014 8 Number of Products under Development by Companies, H2 2014 9 Comparative Analysis by Clinical Stage Development, H2 2014 10 Comparative Analysis by Early Stage Development, H2 2014 11 Products under Development by Companies, H2 2014 12 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Altor BioScience Corporation, H2 2014 13 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by AstraZeneca PLC, H2 2014 14 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Boston Biomedical, Inc., H2 2014 15 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 16 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Dendreon Corporation, H2 2014 17 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Mirati Therapeutics Inc., H2 2014 18 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Novartis AG, H2 2014 19 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Sanofi, H2 2014 20 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 21 Assessment by Monotherapy Products, H2 2014 22 Number of Products by Stage and Target, H2 2014 24 Number of Products by Stage and Mechanism of Action, H2 2014 26 Number of Products by Stage and Route of Administration, H2 2014 28 Number of Products by Stage and Molecule Type, H2 2014 30 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) Therapeutics - Recent Pipeline Updates, H2 2014 49 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Dormant Projects, H2 2014 54 Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Discontinued Products, H2 2014 55
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.